Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT06235567
Other study ID # 23-40498
Secondary ID
Status Enrolling by invitation
Phase Phase 1/Phase 2
First received
Last updated
Start date April 2024
Est. completion date December 2024

Study information

Verified date March 2024
Source University of California, San Francisco
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study aims to compare the use of Dextenza, an FDA-approved intracanilular drug-eluting insert that is designed to deliver a tapered dose of dexamethasone to the ocular surface for 30 days, to the standard of care, or the use of a month-long topical prednisolone acetate 1% (PredForte) eye drops starting from four times daily. Following treatment, Dextenza resorbs and exits the nasolacrimal system without the need for removal. Three prior phase 3 clinical trials have demonstrated that Dextenza is equally efficacious to a month-long topical Pred Forte taper in the treatment of postoperative inflammation following cataract surgery. This proposed study strives to demonstrate the non-inferiority of using Dextenza to treat postoperative inflammation following corneal collagen crosslinking compared to standard of care eye drops in a randomized trial. By demonstrating Dextenza's non-inferiority to treatment postoperative inflammation, the investigators hope to provide an alternative modality of treatment to patients who are unable to cooperate with or tolerate postoperative topical eye drop regimens, allowing for improved adherence to necessary therapy and thus improved postoperative outcomes.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 20
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 13 Years to 64 Years
Eligibility Inclusion Criteria: - The study will enroll patients age 13 and up with progressive keratoconus (KCN) who are scheduled for bilateral epithelial off corneal collagen cross-linking (CXL) with Photrexa. A patient's study eye must meet the following criteria to be eligible for inclusion in the study: 1. Progressive keratoconus as defined by increasing astigmatism and/or keratometry on corneal topography or tomography or increasing cylindrical error on refraction 2. Patients requiring general anesthetic for the procedure 3. Preoperative central corneal thickness of >= 400 microns Exclusion Criteria: - History of acute hydrops in treated eye - History of pre-existing severe corneal scarring in the treated eye - History of pre-existing glaucoma in the treated eye - History of or pharmaceutical treatment of glaucoma or ocular hypertension and history or current spikes in intraocular pressure (IOP) in either eye. - History of pre-existing ocular inflammation or infection (conjunctivitis, keratitis, uveitis, or retinitis) in treated eye - Active infectious systemic disease - Obstructed nasolacrimal duct in the study eye(s) - Patients with a nasolacrimal duct smaller than 0.4 mm or greater than or equal to 1.0 mm. - Patients with stenosis to the location where the insert will be placed should be excluded from the study, as the study team would not engage in surgical procedures to expand or surgically correct that region - Hypersensitivity to dexamethasone - Patients being treated with immunomodulating agents in the study eye(s) - Patients being treated with immunosuppressants and/or oral steroids - Patients with severe disease that warrants critical attention, deemed unsafe for the study by the investigator

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Dextenza 0.4Mg Ophthalmic Insert
This insert allows for sustained release of dexamethasone onto the ocular surface over a period of 28 days. It requires a single application and eliminates the potential for noncompliance, difficulty in administration and poor accuracy. Dextenza has been FDA approved for post-operative pain and inflammation following ophthalmic surgery. The pivotal trials included patients undergoing cataract surgery, not CXL surgery. In addition, the age range did not include those of pediatric age.
topical prednisolone acetate 1% (PredForte) eye drops
The patient will administer the anti-inflammatory steroid drops on the same 4 week post-operative schedule that is commonly used in standard of care. They will do one drop of Pred Forte in the affected eye 4 times a day for a week, 3 times a day for the second week, 2 times a day for the third week, and once a day for the fourth week.

Locations

Country Name City State
United States Mission Bay Hospital San Francisco California
United States UCSF Pediatric Ophthalmology San Francisco California
United States Wayne and Gladys Center for Vision San Francisco California

Sponsors (1)

Lead Sponsor Collaborator
Maanasa Indaram, MD

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Corneal haze Assess the efficacy of the dexamethasone insert compared to corticosteroid drops for post-treatment in patients who have had epithelium-off corneal collagen cross linking procedure.
This will be assessed by
-Postoperative corneal haze as measured by the Physician with a slit lamp biomicroscopy and graded on a scale of 0-4+ (0 = least haze ; 4= most haze)
6 months (180 days)
Primary Corneal re-epithelialization Assess the efficacy of the dexamethasone insert compared to corticosteroid drops for post-treatment in patients who have had epithelium-off corneal collagen cross linking procedure.
This will be assessed by
-Physician measured corneal re-epithelialization after bandage contact lens removal by slit lamp biomicroscopy.
6 months (180 days)
Primary Keratometry Assess the efficacy of the dexamethasone insert compared to corticosteroid drops for post-treatment in patients who have had epithelium-off corneal collagen cross linking procedure.
This will be assessed by
Postoperative keratometry values (diopters) as measured by corneal topography or Pentacam tomography. Comparing the pre- to post- operative values.
6 months (180 days)
Primary Infection Adverse event end point: Postoperative infection as measured at any visit. 6 months (180 days)
Secondary Comfort To determine the effect of dexamethasone intracanalicular insert through day 180 as measured by:
- Patient comfort postoperatively as measured by a 0-10 scale and determined by asking the patient (0= no comfort; 10= maximum comfort)
6 months (180 days)
Secondary Ocular Pain Assessment To determine the effect of dexamethasone intracanalicular insert through day 180 as measured by:
- Patient pain postoperatively as measured by a 0-10 scale and determined by asking the patient (0= no pain ; 10= maximum pain)
6 months (180 days)
Secondary Ease of insertion To determine the effect of dexamethasone intracanalicular insert through day 180 as measured by:
- Physician ease of insertion as measured by a 0-5-point scale (0= easy insertion ; 5= difficult insertion)
6 months (180 days)
Secondary Comparison of Ophthalmic Medications for Tolerability Questionnaire To determine the effect of dexamethasone intracanalicular insert through day 180 as measured by:
- Patient's and caregivers' therapy of preference as measured by the Comparison of Ophthalmic Medications for Tolerability Questionnaire (COMTOL)
6 months (180 days)
Secondary IOP spikes incidence To determine the effect of dexamethasone intracanalicular insert through day 180 as measured by:
- Incidence of IOP spikes (IOP increased >or = 10mmHg from baseline) measured
6 months (180 days)
Secondary Anterior segment OCT To determine the effect of dexamethasone intracanalicular insert through day 180 as measured by:
- Anterior segment OCT findings mean change from baseline
6 months (180 days)
Secondary Best Corrected Visual Acuity To determine the effect of dexamethasone intracanalicular insert through day 180 as measured by:
- Best corrected visual acuity mean change from baseline as measured
6 months (180 days)
See also
  Status Clinical Trial Phase
Recruiting NCT04570020 - Scleral Lens Fitting Using Wide-Field OCT
Recruiting NCT02921009 - McNeel Eye Center Corneal Crosslinking Study N/A
Completed NCT01691651 - Botulinum Toxin A for the Treatment of Keratoconus N/A
Terminated NCT02762253 - Study of the Safety and Effectiveness of Photochemically Induced Collagen Cross-Linking in Eyes With Keratoconus. Phase 2
Completed NCT01527708 - Accuracy of Curvature and Wavefront Aberrations of Posterior Corneal Surface, in Keratoconic and Post-CXL Corneas N/A
Completed NCT01527721 - Blurring Strength & Aberrometric Changes Following Corneal Cross-linking (CxL) and CxL Combined With Photorefractive Keratectomy (PRK) in Keratoconus N/A
Recruiting NCT00841386 - Treatment of Keratoconus Using Collagen Cross-Linking Phase 2/Phase 3
Completed NCT00347074 - A Clinical Study of Keratoconus in Asian Patients and Assessment of Different Topographic Patterns of Keratoconus in Asian Patients N/A
Completed NCT03187912 - Accelerated Corneal Cross-linking With Different Riboflavin Solutions Phase 3
Completed NCT00584285 - Corneal Topographer Fluorescein Patterns
Completed NCT03511495 - Reliability of Topography Measurements in Keratoconus
Not yet recruiting NCT05395650 - Cyanocobalamin as Photosensitizing Agent
Completed NCT04418999 - Safety and Efficacy of Intracanalicular Dexamethasone Compared to Loteprednol Etabonate in Patients With Keratoconus Early Phase 1
Completed NCT03235856 - Retrospective Digital Computer Analysis of Keratoconus Evolution - REDCAKE
Completed NCT05019768 - Topo-pachimetric Accelerated Epi-On Cross-linking Compared to Dresden Protocol Using Riboflavin With Vitamin E TPGS N/A
Withdrawn NCT01789333 - Higher Irradiance in Keratoconus Ectasia N/A
Completed NCT05114928 - Correlation Between Q-value Changes and Progression of Pediatric Keratoconus.
Completed NCT03647046 - Custom Anterior Surfacing of Scleral Lens for Vision Quality Improvement in Patients With Keratoconus N/A
Recruiting NCT04439552 - fMRI and IVCM Cornea Microscopy of CXL in Keratoconus
Recruiting NCT06100939 - Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus Phase 3